Exploring the Anti-ageing Effects of Metformin in COPD

Prospective, multicentre, double-blind, placebo-controlled, randomised, prospective clinical trial comparing the effect of metformin 850 mg twice daily with placebo in COPD patients with evidence of emphysema (by CT scan or reduced DLCO) who are known to have a rapid decrease in FEV1. Main objective: To compare the change in FEV1 at 3 years follow-up in patients receiving metformin versus placebo. Participants will take metformin (850mg) or placebo twice daily for 3 years.

NCT Number	NCT06999343
Lead Sponsor	Fundación Instituto de Investigación Sanitaria de Navarra
Conditions	COPD
Enrollment	212 participants
Start Date	2025-09-01
Primary Completion	2029-05-01 (estimated)
Study Completion	2029-09-01 (estimated)
Updated on ClinicalTrials.gov	2025-05-31